Biblio
Journal Article
Fregona V, Bayet M, Bouttier M, Largeaud L, Hamelle C, Jamrog LA, Prade N, Lagarde S, Hébrard S, Luquet I, et al. Stem cell-like reprogramming is required for leukemia-initiating activity in B-ALL. J Exp Med. 2024;221(1).
Canali A, Vergnolle I, Bertoli S, Largeaud L, Nicolau M-L, Rieu J-B, Tavitian S, Huguet F, Picard M, Bories P, et al. Prognostic impact of unsupervised early assessment of bulk and leukemic stem cell measurable residual disease in acute myeloid leukemia. Clin Cancer Res. 2022.
Bouvier A, Hamel J-F, Delaunay J, Delabesse E, Dumas P-Y, Ledoux MPierre, Peterlin P, Luquet I, Guepin GRoth, Bulabois CEric, et al. Molecular classification and prognosis in younger adults with acute myeloid leukemia patients and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: final results of the GOELAMS/FILO AML 2006-IR trial. Eur J Haematol. 2021.
Emadali A, Hoghoughi N, Duley S, Hajmirza A, Verhoeyen E, Cosset F-L, Bertrand P, Roumier C, Roggy A, Suchaud-Martin C, et al. Haploinsufficiency for NR3C1, the gene encoding the glucocorticoid receptor, in blastic plasmacytoid dendritic cell neoplasms. Blood. 2016.
Lafage-Pochitaloff M, Gerby B, Baccini V, Largeaud L, Fregona V, Prade N, Juvin P-Y, Jamrog LAudrey, Bories P, Hébrard S, et al. The CADM1 tumor suppressor gene is a major candidate gene in MDS with deletion of the long arm of chromosome 11. Blood Adv. 2021.
]